R. Hammond

532 total citations
20 papers, 383 citations indexed

About

R. Hammond is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, R. Hammond has authored 20 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 16 papers in Hepatology and 6 papers in Infectious Diseases. Recurrent topics in R. Hammond's work include Hepatitis B Virus Studies (18 papers), Hepatitis C virus research (16 papers) and Liver Disease Diagnosis and Treatment (10 papers). R. Hammond is often cited by papers focused on Hepatitis B Virus Studies (18 papers), Hepatitis C virus research (16 papers) and Liver Disease Diagnosis and Treatment (10 papers). R. Hammond collaborates with scholars based in Australia, United States and Singapore. R. Hammond's co-authors include H Kelly, J Leydon, Philip Kiely, William J. Maskill, Heath Kelly, Stephen Locarnini, S. Bowden, D. Scott Bowden, Suzanne M. Garland and Harin Karunajeewa and has published in prestigious journals such as Gastroenterology, PLoS ONE and Gut.

In The Last Decade

R. Hammond

19 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Hammond Australia 10 263 216 145 84 33 20 383
B Litwińska Poland 10 136 0.5× 25 0.1× 176 1.2× 65 0.8× 24 0.7× 45 317
Valérie Barlet France 13 237 0.9× 226 1.0× 99 0.7× 15 0.2× 5 0.2× 25 384
Barbara Hottenträger Germany 10 102 0.4× 78 0.4× 268 1.8× 171 2.0× 90 2.7× 18 361
Lise Heilmann Jensen Denmark 9 85 0.3× 15 0.1× 87 0.6× 23 0.3× 16 0.5× 20 190
Bùi Tiến Sỹ Vietnam 11 199 0.8× 229 1.1× 88 0.6× 11 0.1× 4 0.1× 26 313
Şener Barut Türkiye 10 123 0.5× 110 0.5× 109 0.8× 3 0.0× 5 0.2× 38 303
A. Tounkara Mali 12 117 0.4× 30 0.1× 159 1.1× 7 0.1× 8 0.2× 25 338
P C Kelly United States 7 301 1.1× 23 0.1× 185 1.3× 10 0.1× 6 0.2× 11 343
Inara E. Souza United States 7 225 0.9× 48 0.2× 112 0.8× 4 0.0× 39 1.2× 13 291
P Hegener Germany 8 137 0.5× 66 0.3× 89 0.6× 4 0.0× 5 0.2× 9 303

Countries citing papers authored by R. Hammond

Since Specialization
Citations

This map shows the geographic impact of R. Hammond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Hammond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Hammond more than expected).

Fields of papers citing papers by R. Hammond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Hammond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Hammond. The network helps show where R. Hammond may publish in the future.

Co-authorship network of co-authors of R. Hammond

This figure shows the co-authorship network connecting the top 25 collaborators of R. Hammond. A scholar is included among the top collaborators of R. Hammond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Hammond. R. Hammond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Walsh, Renae, R. Hammond, Carina C. D. Joe, et al.. (2023). Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector. Viruses. 15(2). 313–313. 2 indexed citations
3.
Rubio, Aileen, et al.. (2023). A monoclonal antibody 4G2 exhibits anti-viral activity in mouse models of chronic hepatitis B. Journal of Hepatology. 78. S1164–S1164.
4.
Lai, Fritz, Kiren Purushotorman, Conrad En Zuo Chan, et al.. (2022). Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus. npj Vaccines. 7(1). 121–121. 3 indexed citations
5.
Xu, Hui, Stephen Locarnini, Darren Wong, et al.. (2021). Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. Journal of Hepatology. 76(1). 34–45. 21 indexed citations
6.
Walsh, Renae, R. Hammond, Lilly Yuen, et al.. (2019). Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure. Liver International. 39(11). 2066–2076. 7 indexed citations
7.
Walsh, Renae, R. Hammond, Kathy Merlock Jackson, et al.. (2018). Effects of SB9200 (Inarigivir) therapy on immune responses in patients with chronic hepatitis B. Journal of Hepatology. 68. S89–S89. 5 indexed citations
8.
Locarnini, SA, K. Jackson, Renae Walsh, et al.. (2018). Inarigivir: a novel RIG-I agonist for chronic hepatitis B. 1 indexed citations
9.
10.
Walsh, Renae, R. Hammond, Lilly Yuen, et al.. (2016). Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAI) Therapy Based on HBsAg Epitope Profile Analysis. Journal of Hepatology. 64(2). S602–S602. 3 indexed citations
11.
Bayliss, Julianne, Gillian Rosenberg, A. Thompson, et al.. (2015). P0665 : HBV variants present in treatment naïve patients can predict response to NA therapy in immune clearance disease. Journal of Hepatology. 62. S570–S571. 1 indexed citations
12.
Rosenberg, Gillian, Julianne Bayliss, Anuj Gaggar, et al.. (2014). P653 RECLASSIFICATION OF IMMUNOTOLERANT CHRONIC HEPATITIS B INFECTION; DETECTION OF HBV VARIANTS WITH IMPLICATIONS FOR HBV DNA, HBsAg AND HBeAg LEVELS. Journal of Hepatology. 60(1). S286–S286. 1 indexed citations
13.
Gish, Robert G., Kim Bảo Giang, David Adler, et al.. (2014). A simple and inexpensive point‐of‐care test for hepatitis B surface antigen detection: serological and molecular evaluation. Journal of Viral Hepatitis. 21(12). 905–908. 26 indexed citations
14.
Lesmana, Cosmas Rinaldi Adithya, Kathy Merlock Jackson, Seng Gee Lim, et al.. (2014). Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients. United European Gastroenterology Journal. 2(2). 99–107. 10 indexed citations
15.
Matthews, Gail, Anchalee Avihingsanon, Janaki Amin, et al.. (2013). Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals. PLoS ONE. 8(4). e61297–e61297. 40 indexed citations
16.
Holmes, Jacinta A., Tin Nguyen, Neel Heerasing, et al.. (2013). IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon‐α. Journal of Gastroenterology and Hepatology. 28(5). 861–866. 32 indexed citations
17.
Moriconi, F., S. Bowden, R. Hammond, et al.. (2011). Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay. Clinical and Vaccine Immunology. 18(11). 1943–1950. 35 indexed citations
18.
Bowden, D. Scott, Heath Kelly, Kerrie Watson, et al.. (2007). Reduction in Hepatitis C–Related Liver Disease Associated With GB Virus C in Human Immunodeficiency Virus Coinfection. Gastroenterology. 133(6). 1821–1830. 30 indexed citations
19.
Karunajeewa, Harin, David Siebert, R. Hammond, Suzanne M. Garland, & Heath Kelly. (2001). Seroprevalence of varicella zoster virus, parvovirus B19 and Toxoplasma gondii in a Melbourne obstetric population: implications for management. Australian and New Zealand Journal of Obstetrics and Gynaecology. 41(1). 23–28. 26 indexed citations
20.
Kelly, H, et al.. (2000). The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiology and Infection. 124(3). 449–457. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Litwińska Breakdown of academic impact, for papers by Valérie Barlet Breakdown of academic impact, for papers by Barbara Hottenträger Breakdown of academic impact, for papers by Lise Heilmann Jensen Breakdown of academic impact, for papers by Bùi Tiến Sỹ Breakdown of academic impact, for papers by Şener Barut Breakdown of academic impact, for papers by A. Tounkara Breakdown of academic impact, for papers by P C Kelly Breakdown of academic impact, for papers by Inara E. Souza Breakdown of academic impact, for papers by P Hegener
Rankless by CCL
2026